Evidence map›Paper›PMID 35116085›Full record

ArticleThe annals of applied statistics2021

ZERO-INFLATED QUANTILE RANK-SCORE BASED TEST (ZIQRANK) WITH APPLICATION TO SCRNA-SEQ DIFFERENTIAL GENE EXPRESSION ANALYSIS.

Wodan Ling, Wenfei Zhang, Bin Cheng, Ying Wei

Abstract read
In one paragraph

Article in The annals of applied statistics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wodan LingPublic Health Sciences Division, Fred Hutchinson Cancer Research Center.
Wenfei ZhangSarepta Therapeutics.
Bin ChengDepartment of Biostatistics, Columbia University.
Ying WeiDepartment of Biostatistics, Columbia University.

Funding

High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
NIH HHS S10 OD020069NIH HHS S10 OD028685
6 · The paper itself

Abstract

Differential gene expression analysis based on scRNA-seq data is challenging due to two unique characteristics of scRNA-seq data. First, multimodality and other heterogeneity of the gene expression among different cell conditions lead to divergences in the tail events or crossings of the expression distributions. Second, scRNA-seq data generally have a considerable fraction of dropout events, causing zero inflation in the expression. To account for the first characteristic, existing parametric approaches targeting the mean difference in gene expression are limited, while quantile regression that examines various locations in the distribution will improve the power. However, the second characteristic, zero inflation, makes the traditional quantile regression invalid and underpowered. We propose a quantile-based test that handles the two characteristics, multimodality and zero inflation, simultaneously. The proposed quantile rank-score based test for differential distribution detection (ZIQRank) is derived under a two-part quantile regression model for zero-inflated outcomes. It comprises a test in logistic modeling for the zero counts and a collection of rank-score tests adjusting for zero inflation at multiple prespecified quantiles of the positive part. The testing decision is based on an aggregate result by combining the marginal

Indexed as

Heterogeneitymultimodalityquantile rank-score based testtwo-part model

Identifiers

PMID35116085
PMCPMC8809477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.